摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

δ-amino-1,2-dihydroxy-4-butylbenzene | 52336-46-6

中文名称
——
中文别名
——
英文名称
δ-amino-1,2-dihydroxy-4-butylbenzene
英文别名
1,2-Benzenediol, 4-(4-aminobutyl)-;4-(4-aminobutyl)benzene-1,2-diol
δ-amino-1,2-dihydroxy-4-butylbenzene化学式
CAS
52336-46-6
化学式
C10H15NO2
mdl
——
分子量
181.235
InChiKey
HYUZDHUWLUSNER-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.3
  • 重原子数:
    13
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    66.5
  • 氢给体数:
    3
  • 氢受体数:
    3

文献信息

  • Sodium channel blockers
    申请人:PARION SCIENCES, Inc.
    公开号:US20040198747A1
    公开(公告)日:2004-10-07
    The present invention relates to sodium channel blockers. The present invention also relates to a variety of methods of treatment using these sodium channel blockers.
    本发明涉及钠通道阻滞剂。本发明还涉及使用这些钠通道阻滞剂的各种治疗方法。
  • Pyrimidinone derivatives, processes for preparing them and pharmaceutical compositions containing them
    申请人:SMITH KLINE & FRENCH LABORATORIES LIMITED
    公开号:EP0013071A1
    公开(公告)日:1980-07-09
    The invention provides new histamine H2- antagonist compounds of Structure 1 in which R' is hydrogen, lower alkyl, lower alkoxy, hydroxy, halogen, trifluoromethyl, nitro, amino, lower alkylamino, lower alkanoylamino, di(lower alkyl)amino or cyano; R2 is in the 3-, 4- or 5- position and is hydrogen, or R2 is lower alkyl substituted by amino, lower alkylamino, di(lower alkyl)amino, N-piperidino or N-pyrollidino, or R2 is ethoxy or propoxy w-substituted by amino, lower alkylamino, di(lower alkyl)amino, N-piperidino or N-pyrollidino; Y is methylene or oxygen and X is methylene or sulphur provided that one or two of the groups X and Y is methylene; Z is hydrogen or lower alkyl; A is C1-C5 alkylene or-(CH2)pW-(CH2)q-where W is oxygen or sulphur and p and q are such that their sum is from 1 to4, and B is hydrogen, methyl, C3-C6 cycloalkyl, a heteroaryl group optionally substituted by one or more of the groups lower alkyl, lower alkoxy, halo, hydroxy and amino, or B is a naphthyl, 6-(2,3-dihydro-1,4-benzodioxinyl), a 4- or 5-(1,3-benzodioxolyl) group, or a phenyl group optionally substituted with one or more lower alkyl, lower alkoxy, halogen, aryl(lower alkoxy), hydroxy, lower alkoxy-lower alkoxy, trifluoromethyl, di(lower alkyl)amino, phenoxy, halophenoxy, lower alkoxyphenoxy, phenyl, halophenyl or lower alkoxyphenyl groups and pharmaceutical compositions containing them. A compound of Structure 1 can be prepared by reacting a compound of Structure 3 in which Q is nitroamino, loweralkylthio, benzylthio or halogen with an amine of Structure 2, in which R3 is in the 3-, 4- or 5p position and is hydrogen, lower alkyl substituted by a group R4, or is R4CH2CH2O-or R4CH2CH2CH2O-, where R' is di(lower alkyl)amino, N-piperidino, N-pyrrollidino, a protected amino group or a protected lower alkylamino group, and where necessary any amino-protecting group present in the substituent R3 is removed.
    本发明提供了结构 1 的新型组胺 H2- 拮抗剂化合物 其中R'是氢、低级烷基、低级烷氧基、羟基、卤素、三氟甲基、硝基、氨基、低级烷基氨基、低级烷酰氨基、二(低级烷基)氨基或氰基;R2 位于 3-、4-或 5-位且为氢,或 R2 为被氨基、低级烷基氨基、二(低级烷基)氨基、N-哌啶基或 N-吡咯烷基取代的低级烷基,或 R2 为被氨基、低级烷基氨基、二(低级烷基)氨基、N-哌啶基或 N-吡咯烷基取代的乙氧基或丙氧基;Y 为亚甲基或氧,X 为亚甲基或硫,条件是 X 和 Y 中的一个或两个基团为亚甲基;Z 为氢或低级烷基;A是C1-C5亚烷基或-(CH2)pW-(CH2)q-其中W是氧或硫,p和q的和为1至4,B是氢、甲基、C3-C6环烷基、任选被一个或多个基团低级烷基、低级烷氧基、卤代、羟基和氨基取代的杂芳基,或者B是萘基、6-(2,3-二氢-1,4-苯并二噁烷基)、4-或5-(1、3-苯并二恶茂基)基团,或任选被一个或多个低级烷基、低级烷氧基、卤素、芳基(低级烷氧基)、羟基、低级烷氧基-低级烷氧基、三氟甲基、二(低级烷基)氨基、苯氧基、卤代苯氧基、低级烷氧基苯氧基、苯基、卤代苯基或低级烷氧基苯基基团取代的苯基基团以及含有它们的药物组合物。结构 1 的化合物可通过结构 3 的化合物(其中 Q 为硝基氨基、低级烷硫基、苄硫基或卤素) 与结构 2 的胺反应制备,其中 R3 位于 3-、4-或 5p 位,是氢、被基团 R4 取代的低级烷基或 R4CH2CH2O- 或 R4CH2CH2CH2O-,其中 R' 是二(低级烷基)氨基、N-哌啶基、N-吡咯烷基、受保护的氨基或受保护的低级烷基氨基,必要时去除取代基 R3 中存在的任何氨基保护基。
  • US4212645A
    申请人:——
    公开号:US4212645A
    公开(公告)日:1980-07-15
  • US4496567A
    申请人:——
    公开号:US4496567A
    公开(公告)日:1985-01-29
  • [EN] NEW HISTAMINE H2-ANTAGONISTS
    申请人:——
    公开号:WO1980000966A1
    公开(公告)日:1980-05-15
    (EN) New histamine H2-antagonist compounds of structure 1 (FORMULA) in which R1 is hydrogen, lower alkyl, lower alkoxy, hydroxy, halogen trifluoromethyl, nitro, amino, lower alkylamino, lower alkanoylamino, di (lower alkyl) amino or cyano; R2 is in the 3-, 4- or 5-position and is hydrogen, R2 is lower alkyl substituted by amino, lower alkylamino, di (lower alkyl) amino, N-piperidino or N-pyrollidino, or R2 is ethoxy or propoxy (Alpha)-substituted by amino, lower alkylamino, di (lower alkyl) amino, N-piperidino or N-pyrollidino; Y is methylene or oxygen and X is methylene or sulphur provided that one or two of the groups X and Y is methylene; Z is hydrogen or lower alkyl; A is C1-C5 alkylene or -(CH2)pW-(CH2)q where W is oxygen or sulphur and p and q are such that their sum is from 1 to 4, and B is hydrogen methyl, C3-C6 cycloalkyl, a heteroaryl group optionally substituted by one or more of the groups lower alkyl, lower alkoxy, halo, hydroxy and amino, or B is naphthyl, 6-(2,3-dihydro-1,4-benzodioxinyl), a4- or 5-(1,3-benzodioxolyl) group, or a phenyl group optionally substituted with one or more lower alkyl, lower alkoxy, halogen, aryl (lower alkoxy), hydroxy, lower alkoxy-lower alkoxy, trifluoromethyl, di (lower alkyl) amino, phenoxy, halophenoxy, lower alkoxyphenoxy, phenyl, halophenyl or lower alkoxyphenyl groups and pharmaceutical compositions containing them. A compound of structure 1 can be prepared by reacting a compound of structure 3 in which Q is nitroamino, loweralkylthio, benzylthio or halogen with an amine of structure 2, in which (FORMULA) R3 is in the 3-, 4- or 5-position and is hydrogen, lower alkyl substituted by a group R4, or is R4CH2CH2O-or R4CH2CH2CH2O-, where R4 is di(lower alkyl)amino, N-piperidino, N-pyrrollidino, a protected amino group or a protected lower alkylamino group, and where necessary any amino-protecting group present in the substituent R3 is removed. (FR) Nouveaux composes antagonistes des recepteurs-H2 de l"histamine, de structure 1 (FORMULE) dans laquelle R1 represente l"hydrogene, un groupe alkyle inferieur, alkoxy inferieur, hydroxy, halogene, trifluoromethyle, nitro, amino, alkylamino inferieur alcanoylamino inferieur, di(alkyle inferieur) aminoe ou cyano; R2 se trouve en position 3-, 4-, ou 5- et represente l"hydrogene ou R2 represente un groupe alkyle inferieur substitue par amino, alkylamino inferieur, di(alkyle inferieur) amino, N-piperidino ou N-pyrrolidino, ou R2 represente un groupe ethoxy ou propoxy (Alpha)-substitue par amino, alkylamino inferieur, di(alkyle inferieur) amino, N-piperidino ou N-pyrrolidino; Y represente un groupe methylene ou l"oxygene et X represente un methylene; Z represente l"hydrogene ou un groupe alkyle inferieur; A represente un groupe alkylene en C1-C5 ou -(CH2)pW-(CH2)q dans lequel W represente l"oxygene ou le soufre et p et q sont tels que leur somme est de 1 a 4, et B represente l"hydrogene, un groupe methyle, cycloalkyle en C3-C6, un groupe heteroaryle facultativement substitue par un ou plus des groupes alkyle inferieurs, alkoxy inferieurs, halo, hydroxy et amino ou B represente un groupe naphtyle, 6-(2,3-dihydro-1,4-benzodioxinyl), un groupe 4- ou 5-(1,3-benzodioxolyl) ou un groupe phenyle facultativement substitue par un ou plus d"un groupe alkyle inferieur, alkoxy inferieur, halogene, aryl (alkoxy inferieur), hydroxy, alkoxy inferieur-alkoxy inferieur, trifluoromethyl, di(alkyle inferieur) amino, phenoxy, halophenoxy, alkoxy inferieur phenoxy, phenyle, alophenyl ou groupes alkoxy inferieur phenyle et les compositions pharmaceutiques les contenant. Un compose de structure 1 peut etre prepare en faisant reagir un compose de structure 3 dans laquelle Q represente un groupe nitroamino, thio-alkyle inferieur, benzylthio ou un halogene avec une amine de structure 2 dans laquelle (FORMULE) R3 est en position 3-, 4- ou 5- et represente l"hydrogene, un groupe alkyl inferieur substitue par un groupe R4 ou represente un groupe R4CH2CH2O- ou R4CH2CH2CH2O- dans lequel R4 represente un groupe di(alkyle inferieur) amino, N-piperidino, N-pyrrolidino, un groupe amino protege ou un groupe akylamino inferieur protege et si necessaire, tout groupe protecteur de groupe amine present dans le substituent R3 est elimine.
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐